Tardive dyskinesia and diabetes mellitus

Linda Ganzini, Daniel Casey, W. F. Hoffman, R. T. Heintz

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Two studies examine the prevalence of tardive dyskinesia (TD) in neuroleptic-treated diabetic patients. Study 1 compared 38 diabetic patients with 38 nondiabetic patients treated for psychotic disorders with low to moderate doses of neuroleptics (mean chlorpromazine equivalents = 300 mg/day) for an average of 18 years. Study 2 compared 24 diabetic and 27 nondiabetic patients treated for an average of 2.6 years with a mean 31 mg/day of metoclopramide for gastrointestinal disease. Patients were examined for TD using standardized scales by raters blind to all treatment and illness variables. In both studies, there were no differences between the diabetic and nondiabetic groups in age, sex, type of psychiatric illness, and dose and duration of neuroleptic treatment or severity of parkinsonism. In both studies, the diabetic patients had significantly greater prevalence and severity of TD. No measures of diabetes severity were associated with TD in either study. Possible pathophysiologic mechanisms for the increased prevalence of TD in neuroleptic-treated patients with diabetes will be discussed.

Original languageEnglish (US)
Pages (from-to)281-286
Number of pages6
JournalPsychopharmacology Bulletin
Volume28
Issue number3
StatePublished - 1992
Externally publishedYes

Fingerprint

Diabetes Mellitus
Antipsychotic Agents
Metoclopramide
Gastrointestinal Diseases
Chlorpromazine
Parkinsonian Disorders
Tardive Dyskinesia
Psychotic Disorders
Psychiatry
Age Groups
Cross-Sectional Studies
Therapeutics

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology

Cite this

Ganzini, L., Casey, D., Hoffman, W. F., & Heintz, R. T. (1992). Tardive dyskinesia and diabetes mellitus. Psychopharmacology Bulletin, 28(3), 281-286.

Tardive dyskinesia and diabetes mellitus. / Ganzini, Linda; Casey, Daniel; Hoffman, W. F.; Heintz, R. T.

In: Psychopharmacology Bulletin, Vol. 28, No. 3, 1992, p. 281-286.

Research output: Contribution to journalArticle

Ganzini, L, Casey, D, Hoffman, WF & Heintz, RT 1992, 'Tardive dyskinesia and diabetes mellitus', Psychopharmacology Bulletin, vol. 28, no. 3, pp. 281-286.
Ganzini L, Casey D, Hoffman WF, Heintz RT. Tardive dyskinesia and diabetes mellitus. Psychopharmacology Bulletin. 1992;28(3):281-286.
Ganzini, Linda ; Casey, Daniel ; Hoffman, W. F. ; Heintz, R. T. / Tardive dyskinesia and diabetes mellitus. In: Psychopharmacology Bulletin. 1992 ; Vol. 28, No. 3. pp. 281-286.
@article{278e49e92883491cab2a237ff3da0d54,
title = "Tardive dyskinesia and diabetes mellitus",
abstract = "Two studies examine the prevalence of tardive dyskinesia (TD) in neuroleptic-treated diabetic patients. Study 1 compared 38 diabetic patients with 38 nondiabetic patients treated for psychotic disorders with low to moderate doses of neuroleptics (mean chlorpromazine equivalents = 300 mg/day) for an average of 18 years. Study 2 compared 24 diabetic and 27 nondiabetic patients treated for an average of 2.6 years with a mean 31 mg/day of metoclopramide for gastrointestinal disease. Patients were examined for TD using standardized scales by raters blind to all treatment and illness variables. In both studies, there were no differences between the diabetic and nondiabetic groups in age, sex, type of psychiatric illness, and dose and duration of neuroleptic treatment or severity of parkinsonism. In both studies, the diabetic patients had significantly greater prevalence and severity of TD. No measures of diabetes severity were associated with TD in either study. Possible pathophysiologic mechanisms for the increased prevalence of TD in neuroleptic-treated patients with diabetes will be discussed.",
author = "Linda Ganzini and Daniel Casey and Hoffman, {W. F.} and Heintz, {R. T.}",
year = "1992",
language = "English (US)",
volume = "28",
pages = "281--286",
journal = "Psychopharmacology Bulletin",
issn = "0048-5764",
publisher = "MedWorks Media LLC",
number = "3",

}

TY - JOUR

T1 - Tardive dyskinesia and diabetes mellitus

AU - Ganzini, Linda

AU - Casey, Daniel

AU - Hoffman, W. F.

AU - Heintz, R. T.

PY - 1992

Y1 - 1992

N2 - Two studies examine the prevalence of tardive dyskinesia (TD) in neuroleptic-treated diabetic patients. Study 1 compared 38 diabetic patients with 38 nondiabetic patients treated for psychotic disorders with low to moderate doses of neuroleptics (mean chlorpromazine equivalents = 300 mg/day) for an average of 18 years. Study 2 compared 24 diabetic and 27 nondiabetic patients treated for an average of 2.6 years with a mean 31 mg/day of metoclopramide for gastrointestinal disease. Patients were examined for TD using standardized scales by raters blind to all treatment and illness variables. In both studies, there were no differences between the diabetic and nondiabetic groups in age, sex, type of psychiatric illness, and dose and duration of neuroleptic treatment or severity of parkinsonism. In both studies, the diabetic patients had significantly greater prevalence and severity of TD. No measures of diabetes severity were associated with TD in either study. Possible pathophysiologic mechanisms for the increased prevalence of TD in neuroleptic-treated patients with diabetes will be discussed.

AB - Two studies examine the prevalence of tardive dyskinesia (TD) in neuroleptic-treated diabetic patients. Study 1 compared 38 diabetic patients with 38 nondiabetic patients treated for psychotic disorders with low to moderate doses of neuroleptics (mean chlorpromazine equivalents = 300 mg/day) for an average of 18 years. Study 2 compared 24 diabetic and 27 nondiabetic patients treated for an average of 2.6 years with a mean 31 mg/day of metoclopramide for gastrointestinal disease. Patients were examined for TD using standardized scales by raters blind to all treatment and illness variables. In both studies, there were no differences between the diabetic and nondiabetic groups in age, sex, type of psychiatric illness, and dose and duration of neuroleptic treatment or severity of parkinsonism. In both studies, the diabetic patients had significantly greater prevalence and severity of TD. No measures of diabetes severity were associated with TD in either study. Possible pathophysiologic mechanisms for the increased prevalence of TD in neuroleptic-treated patients with diabetes will be discussed.

UR - http://www.scopus.com/inward/record.url?scp=0026478943&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026478943&partnerID=8YFLogxK

M3 - Article

VL - 28

SP - 281

EP - 286

JO - Psychopharmacology Bulletin

JF - Psychopharmacology Bulletin

SN - 0048-5764

IS - 3

ER -